Synthesis and SAR of potent and orally bioavailable tert-butylpyrrolidine archetype derived melanocortin subtype-4 receptor modulators

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 11, 2008, Pages 3242-3247

  Guo, Liangqin ^a   Ye, Zhixiong ^a   Ujjainwalla, Feroze ^a   Sings, Heather L ^a   Sebhat, Iyassu K ^a   Huber, John ^a   Weinberg, David H ^a   Tang, Rui ^a   MacNeil, Tanya ^a   Tamvakopoulos, Constantin ^a   Peng, Qianping ^a   MacIntyre, Euan ^a   van der Ploeg, Lex H T ^a   Goulet, Mark T ^a   Wyvratt, Matthew J ^a   Nargund, Ravi P ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

G protein coupled receptor; Melanocortin subtype 4 receptor agonist; Obesity; Oral bioavailability

Indexed keywords

MELANOCORTIN 4 RECEPTOR; PYRROLIDINE DERIVATIVE; TERT BUTYLPYRROLIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG POTENCY; DRUG SYNTHESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION;

ADMINISTRATION, ORAL; HUMANS; MOLECULAR STRUCTURE; PYRROLIDINES; RECEPTOR, MELANOCORTIN, TYPE 4; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TELOMERASE;

EID: 44149120045     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.04.049     Document Type: Article

References (21)

1. Emmerson P.J., Fisher M.J., Yan L.Z., and Mayer J.P. Curr. Top. Med. Chem. 7 (2007) 1121
2. Nargund R.P., Strack A.M., and Fong T.M. J. Med. Chem. 49 (2006) 4035
3. Zimanyi I.A., and Pelleymounter M.A. Curr. Pharm. Des. 9 (2003) 627
4. Van der. Ploeg L.H.T., Howard A.D., Nargund R.P., Austin C.P., Guan X., Drisko J., Cashen D., Sebhat I., Pattchett A.A., Figueroa D.J., DiLella A.G., Connolly D.H., Weinberg D.H., Tan C.T., Palyha O.C., Pong S., MacNeil T., Rosenblum C., Vongs A., Tang R., Yu H., Sailer A.W., Fong T.M., Huang C., Tota M., Chang R.S., Sterns R., Tamvakopoulos T., Christ G., Drazen D.L., Spar B.D., Nelson R.J., and Maclntyre D.E. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 11381
5. Eberle A.N. In: Cone R.D. (Ed). The Melanocortin Receptors (2000), Human Press 3
6. Huszar D., Lynch C.A., Fairchild-Huntress V., Dunmore J.H., Fang Q., Berkemeier L.R., Gu W., Kesterson R.A., Boston B.A., Cone R.D., Smith F.J., Campfield L.A., Burn P., and Lee F. Cell 88 (1997) 131
7. Gu W., Tu Z., Kleyn P.W., Kissebah A., Duprat L., Lee J., Chin W., Maruti S., Deng N., Fisher S.L., Franco L.S., Burn P., Yagaloff K.A., Nathan J., Heymsfield S., Albu J., Pi-Sunyer F.X., and Allison D.B. Diabetes 48 (1999) 635
8. Hinney A., Schmidt A., Nottebom K., Heibult O., Becker I., Ziegler A., Gerber G., Sina M., Gorg T., Mayer H., and Hebebrand J. J. Clin. Endocrinol. Metab. 84 (1999) 1483
9. Ujjainwalla F., and Sebhat I.K. Curr. Top. Med. Chem. 7 (2007) 1068
10. Sebhat I.K., Lai Y., Barakat K., Ye Z., Tang R., Kalyani R.N., Vongs A., MacNeil T., Weinberg D.H., Cabello M.A., Maroto M., Teran A., Fong T.M., Van der Ploeg L.H.T., Patchett A.A., and Nargund R.P. Bioorg. Med. Chem. Lett. 17 20 (2007) 5720
11. Ye Z., Guo L., Barakat K.J., Pollard P.G., Palucki B.L., Sebhat I.K., Bakshi R.K., Tang R., Kalyani R.N., Vongs A., Chen A.S., Chen H.Y., Rosenblum C.I., MacNeil T., Weinberg D.H., Peng Q., Tamvakopoulos C., Miller R.R., Stearns R.A., Cashen D.E., Martin W.J., Metzger J.M., Strack A.M., MacIntyre D.E., Van der Ploeg L.H.T., Patchett A.A., Wyvratt M.J., and Nargund R.P. Bioorg. Med. Chem. Lett. 15 (2005) 3501
12. Ujjainwalla F., Warner D., Snedden C., Grisson R.D., Walsh T.F., Wyvratt M.J., Kalyani R.N., Mac Neil T., Tang R., Weinberg D.H., Van der Ploeg L., and Goulet M.T. Bioorg. Med. Chem. Lett. 15 (2005) 4023
13. Pan K., Scott M.K., Lee D.H.S., Fitzpatrick L.J., Crooke J.J., Rivero R.A., Rosenthal D.I., Vaidya A.H., Zhao B., and Reitz A.B. Bioorg. Med. Chem. 11 (2003) 185
14. Sebhat I.K., Martin W.J., Ye Z., Barakat K., Mosley R.T., Johnston D.B.R., Bakshi R., Palucki B., Weinberg D.H., MacNeil T., Kalyani R.N., Tang R., Sterns R.A., Miller R., Tamvakopoulos C., Strack A., McGowan E., Cashen D.E., Drisko J.E., Hom G.J., Howard A.D., MacIntyre D.E., Van der Ploeg L.H.T., Patchett A.A., and Nargund R.A. J. Med. Chem. 45 (2002) 4589
15. Ujjainwalla, F. Presentation (MEDI-275), 230th ACS National Meeting, Washington, DC, August 28-September 1, 2005.
16. Ujjainwalla, F et al., unpublished results (in preparation).
17. Intermediate 3B was synthesized in a similar way as described in Ref. 3 for compound 1.
18. 50 was defined as the inflection point of the cAMP dose-response curve for any given compounds. Maxi percentage activation [% Max] is the percentage of cAMP accumulation at 10 μM of compound relative to α-MSH.
19. For details about assay protocols see:. Bednarek M.A., MacNeil T., Kalyani R.N., Tang R., Van der Ploeg L.H.T., and Weinberg D.H. J. Med. Chem. 44 (2001) 3665
20. Bednarek M.A., Silva M.V., Arison B., MacNeil T., Kalyani R.N., Huang R.R.C., and Weinberg D.H. Peptides 20 (1999) 401
21. The stereochemistry of 1-tert-butyl-4-aryl pyrrolidine-3-carboxylic acid substructure in 2B is same as in 1 and defined as shown in Ref. 3. The slow eluting isomers discussed in this paper were assumed to have the same stereochemistry as 2B, which is also the slow eluting isomer, under the same chiral HPLC conditions.